| 2021 |
Ito N, Fukumoto S. Congenital hyperphosphatemic conditions caused by the deficient activity of FGF23. Calcif Tiss Int. January 2021;108(1):104-115. |
1 |
1 |
| 2004 |
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. March 2004;19(3):429-435. |
24 |
22 |
| 2021 |
Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S. Interim analysis of a phase 2 open‐label trial assessing burosumab efficacy and safety in patients with tumor‐induced osteomalacia. J Bone Miner Res. February 2021;36(2):262-270. |
2 |
1 |
| 2022 |
Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N. Clinical challenges in diagnosis, tumor localization and treatment of tumor-induced osteomalacia: outcome of a retrospective surveillance. J Bone Miner Res. August 2022;37(8):1479-1488. |
0 |
0 |
| 2022 |
Pasieka JL, Wentworth K, Yeo CT, Cremers S, Dempster D, Fukumoto S, Goswami R, Houillier P, Levine MA, Pasternak JD, Perrier ND, Sitges-Serra A, Shoback DM. Etiology and pathophysiology of hypoparathyroidism: a narrative review. J Bone Miner Res. December 2022;37(12):2586-2601. |
5 |
4 |